HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION
Slide Note
Embed
Share

Heart-lung transplantation data from 2012 offers valuable insights into transplant numbers, survival rates, recipient details, and diagnoses. The visuals depict trends in transplants reported, center volumes, distribution by lung center volume, Kaplan-Meier survival analysis, and diagnoses in adult recipients.

  • Heart-Lung Transplantation
  • Transplant Data
  • Survival Rates
  • 2012 Insights
medidoc
medidoc Follow

Uploaded on Feb 15, 2025 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.

Download Presentation

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.

E N D

Presentation Transcript

  1. HEART-LUNG TRANSPLANTATION Overall ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  2. NUMBER OF HEART-LUNG TRANSPLANTS REPORTED BY YEAR 300 250 Number of Transplants 200 150 100 50 0 NOTE: This figure includes only the heart-lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as evidence that the number of heart-lung transplants worldwide has declined in recent years. ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  3. AVERAGE CENTER VOLUME Heart-Lung Transplants: January 1, 2000 - June 30, 2011 60 60 55 55 % of Heart-Lung Transplants 50 50 Number of Centers 45 45 40 40 35 35 30 30 55 25 25 41 20 20 15 15 10 10 5 5 7 4 0 0 1/year 2/year 3/year 4-9/year Average number of heart-lung transplants per year Number of centers Percentage of transplants ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  4. DISTRIBUTION OF HEART-LUNG TRANSPLANTS BY LUNG CENTER VOLUME Heart-Lung Transplants: January 1, 2000 - June 30, 2011 40 % of Heart-Lung Transplants 35 30 25 20 15 10 5 0 1-4 5-9 Average number of lung transplants per year 10-19 20-29 30-39 40-49 50+ ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  5. HEART-LUNG TRANSPLANTATION Kaplan-Meier Survival for All Ages (Transplants: January 1982 - June 2010) 100 Half-life = 3.2 years Conditional Half-life = 9.7 years f 80 N = 4,225 Survival (%) 60 40 N at risk at 23 years = 22 20 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  6. HEART-LUNG TRANSPLANTATION Adult Recipients ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  7. DIAGNOSIS IN ADULT HEART-LUNG TRANSPLANTS (Transplants: January 1982 - June 2011) IPF 4% CF 14% IPAH 28% Other includes cancer, LAM, OB, bronchiectasis COPD/Alpha-1 6% Re-transplant 2% Sarcoidosis 2% Other 4% Acquired heart disease 5% Congenital heart disease 36% ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  8. DIAGNOSIS IN ADULT HEART-LUNG TRANSPLANTS (Transplants: January 1982 - June 2011) Diagnosis Congenital Heart Disease N (%) 1,134 (35.7%) Idiopathic Pulmonary Arterial Hypertension 877 (27.6%) Cystic Fibrosis 448 (14.1%) Acquired Heart Disease 160 (5.0%) COPD/Emphysema 133 (4.2%) Idiopathic Pulmonary Fibrosis 115 (3.6%) Alpha-1 61 (1.9%) Sarcoidosis 52 (1.6%) Re-Transplant: Not Obliterative Bronchiolitis 36 (1.1%) Re-Transplant: Obliterative Bronchiolitis 22 (0.7%) Bronchiectasis 30 (0.9%) Obliterative Bronchiolitis (not Re-Transplant) 24 (0.8%) Other 88 (2.8%) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  9. DIAGNOSIS IN ADULT HEART-LUNG TRANSPLANTS BY ERA (Transplants: January 1982 - June 2011) 100% Other 90% Sarcoidosis 80% Re-TX 70% % of Transplants IPF 60% COPD/Alpha-1 50% Acquired Heart Disease 40% CF 30% IPAH 20% Congenital Heart Disease 10% 0% 2002-6/2011 (N=768) 1982-1991 (N=959) 1992-2001 (N=1,453) Other includes OB (non-ReTX) and Bronchiectasis ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  10. ADULT HEART-LUNG TRANSPLANTS Major Indications By Year (%) Congenital Heart Disease Cystic Fibrosis Retransplant IPAH COPD/Alpha-1 Acquired Heart Disease 100 90 80 % of Transplants 70 60 50 40 30 20 10 0 Transplant Year ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  11. ADULT HEART-LUNG TRANSPLANTS Major Indications By Year (Number) Congenital Heart Disease Cystic Fibrosis Retransplant IPAH COPD/Alpha-1 Acquired Heart Disease 180 160 Number of Transplants 140 120 100 80 60 40 20 0 Transplant Year ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  12. ADULT HEART-LUNG TRANSPLANTS Age Distribution By Location (Transplants: January 2000 - June 2011) 18 - 34 years 35 - 49 years 50 - 59 years 60+ years 100% 80% % of Transplants 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  13. ADULT HEART-LUNG TRANSPLANTS Diagnosis Distribution By Location (Transplants: January 2000 - June 2011) Congenital heart disease IPAH Cystic Fibrosis Acquired heart disease IPF Other 100% 80% % of Transplants 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  14. ADULT HEART-LUNG TRANSPLANTS Donor Age Distribution By Location (Transplants: January 2000 - June 2011) 6-11 12-17 18-34 35-49 50-59 60+ 100% 80% % of Donors 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  15. ADULT HEART-LUNG TRANSPLANTS Kaplan-Meier Survival (Transplants: January 1982 - June 2010) 100 Half-life = 3.3 years Conditional Half-life = 10.0 years f 75 N = 3,544 Survival (%) 50 N at risk at 23 years = 18 25 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  16. ADULT HEART-LUNG TRANSPLANTS Kaplan-Meier Survival by Era (Transplants: January 1982 - June 2010) 100 Half-life (Years): 1982-1991 = 1.9; 1992-2001 = 3.7; 2002-6/2010 = 6.1 Conditional Half-life (Years): 1982-1991 = 8.9; 1992-2001 = 10.0; 2002-6/2010 = NA 75 Survival (%) 50 1982-1991 (N=1,210) 1992-2001 (N=1,588) 2002-6/2010 (N=746) 25 p-value comparing all < 0.0001 0 0 1 2 3 4 5 6 7 8 9 10 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  17. ADULT HEART-LUNG TRANSPLANTS Kaplan-Meier Survival By Diagnosis (Transplants: January 1990 - June 2010) 100 Other Congenital (N = 319) Eisenmenger's Syndrome (N = 621) IPAH (N = 638) 75 Survival (%) HALF-LIFE Congenital: 2.8 Years; Eisenmenger's: 5.5 Years; IPAH: 4.5 Years 50 25 Congenital vs. Eisenmenger's: p = 0.0248 Congenital vs. IPAH: p = 0.0788 Eisenmenger's vs. IPAH: p = 0.4168 0 0 1 2 3 4 5 6 7 Years 8 9 10 11 12 13 14 15 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  18. ADULT HEART-LUNG TRANSPLANTS Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1990 - June 2010) 100 Other Congenital (N = 178) Eisenmenger's Syndrome (N = 413) IPAH (N = 431) 75 Survival (%) 50 HALF-LIFE Congenital: 13.6 Years; Eisenmenger's: 11.1 Years; IPAH: 10.1 Years 25 Congenital vs. Eisenmenger's: p = 0.6985 Congenital vs. IPAH: p = 0.4258 Eisenmenger's vs. IPAH: p = 0.1062 0 0 1 2 3 4 5 6 7 Years 8 9 10 11 12 13 14 15 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  19. ADULT HEART-LUNG RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: April 1994 June 2011) 100% 80% 60% 40% No Activity Limitations Performs with Some Assistance Requires Total Assistance 20% 0% 1 Year (N = 264) 3 Years (N = 213) 5 Years (N = 181) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  20. ADULT HEART-LUNG RECIPIENTS Functional Status of Surviving Recipients US Recipients Only (Follow-ups: March 2005 June 2011) 100% 10% 20% 80% 30% 40% 60% 50% 60% 40% 70% 80% 20% 90% 100% 0% 1 Year (N = 145) 3 Years (N = 94) 2 Years (N = 107) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  21. ADULT HEART-LUNG RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: April 1994 June 2011) 100% 80% Working (FT/PT status unknown) Retired 60% Not Working 40% Working Part Time Working Full Time 20% 0% 5 Years (N = 220) 3 Years (N = 246) 1 Year (N = 348) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  22. ADULT HEART-LUNG RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 June 2011) 100% 80% 60% 40% No Hospitalization Hospitalized, Rejection Only Hospitalized, Rejection and Infection Hospitalized, Not Rejection/Not Infection Hospitalized, Infection Only 20% 0% Up to 1 Year (N = 441) Between 4 and 5 Years (N = 258) Between 2 and 3 Years (N = 314) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  23. ADULT HEART-LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2001 June 2011) 70 60 50 % of Patients 40 30 20 10 0 Any Induction (N=174) Polyclonal ALG/ATG (N=66) OKT3 (N=5) IL-2R Antagonist (N=87) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 Analysis is limited to patients who were alive at the time of the discharge 2012

  24. ADULT HEART-LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2000 December 2010) 100 Any Induction Polyclonal ALG/ATG 90 OKT3 IL-2R Antagonist 80 70 % of Patients 60 50 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 Analysis is limited to patients who were alive at the time of the discharge 2012

  25. ADULT HEART-LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2000 December 2010) 90 80 70 60 % of Patients 50 40 30 20 10 0 Any Induction Polyclonal ALG/ATG OKT3 IL-2R Antagonist ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 Analysis is limited to patients who were alive at the time of the discharge 2012

  26. ADULT HEART-LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January 2001 June 2011) 100 90 Year 1 (N = 206) Year 5 (N = 130) 80 70 % of Patients 60 50 40 30 20 10 0 Cyclosporine Tacrolimus Sirolimus/ Everolimus MMF/MPA Azathioprine Prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 Analysis is limited to patients who were alive at the time of the follow-up 2012

  27. ADULT HEART-LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January 2001 June 2011) 100% Other None 80% Sirolimus/Everolimus + Calcineurin + Cellcycle Sirolimus/Everolimus + Calcineurin 60% Tacrolimus 40% Tacrolimus + MMF/MPA Tacrolimus + AZA 20% Cyclosporine + MMF/MPA 0% Cyclosporine + AZA Year 1 (N = 206) NOTE: Different patients are analyzed in Year 1 and Year 5 Year 5 (N = 130) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 Analysis is limited to patients who were alive at the time of the follow-up 2012

  28. POST-HEART-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Morbidity Rates in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 - June 2011) Within 1 Year 59.0% Total number with known response (N = 405) Outcome Hypertension 18.7% (N = 439) Renal Dysfunction 11.8% Abnormal Creatinine < 2.5 mg/dl 3.0% Creatinine > 2.5 mg/dl 3.6% Chronic Dialysis Renal Transplant 0.2% 26.7% (N = 427) Hyperlipidemia 19.0% (N = 441) Diabetes 3.2% (N = 348) Coronary Artery Vasculopathy 8.4% (N = 415) Bronchiolitis Obliterans Syndrome ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  29. POST-HEART-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Morbidity Rates in Survivors within 5 Years Post-Transplant (Follow-ups: April 1994 - June 2011) Within 5 Years 88.1% Total number with known response (N = 143) Outcome Hypertension 46.2% (N = 169) Renal Dysfunction 32.5% Abnormal Creatinine < 2.5 mg/dl 10.1% Creatinine > 2.5 mg/dl 2.4% Chronic Dialysis 1.2% Renal Transplant 69.3% (N = 150) Hyperlipidemia 28.1% (N = 167) Diabetes 8.0% (N = 87) Coronary Artery Vasculopathy 26.4% (N = 140) Bronchiolitis Obliterans Syndrome ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  30. Freedom from Coronary Artery Vasculopathy and Bronchiolitis Obliterans Syndrome For Adult Heart-Lung Recipients (Follow-ups: April 1994 June 2011) 100 % Free from CAV and Bronchiolitis 90 Obliterans Syndrome 80 70 60 Freedom from Coronary Artery Vasculopathy 50 Freedom from Bronchiolitis Obliterans Syndrome 40 0 1 2 3 4 5 6 7 8 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  31. Freedom from Coronary Artery Vasculopathy For Adult Heart-Lung Recipients By Diagnosis Type (Follow-ups: April 1994 June 2011) 100 90 % Free from CAV 80 70 Heart (N=195) Lung (N=56) Heart/Lung (N=89) 60 p-value comparing all = 0.5290 50 0 1 2 3 4 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  32. Freedom from Bronchiolitis Obliterans Syndrome For Adult Heart-Lung Recipients By Diagnosis Type (Follow-ups: April 1994 June 2011) 100 Heart (N=226) % Free from Bronchiolitis Lung (N=69) 90 Obliterans Syndrome Heart/Lung (N=111) 80 70 60 p-value comparing all = 0.8796 50 0 1 2 3 4 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  33. Freedom from Severe Renal Dysfunction* For Adult Heart-Lung Recipients (Follow-ups: April 1994 June 2011) 100 % Free from Severe Renal Dysfunction 90 80 70 *Severe renal dysfunction = Creatinine > 2.5 mg/dl (221 mol/L), dialysis or renal transplant 60 50 0 1 2 3 4 5 6 7 8 9 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  34. MALIGNANCY POST-HEART-LUNG TRANSPLANT FOR ADULTS Cumulative Morbidity Rates in Survivors (Follow-ups: April 1994 June 2011) 1-Year Survivors 5-Year Survivors 10-Year Survivors Malignancy/Type 421 (94.2%) 155 (88.6%) 50 (83.3%) No Malignancy 26 (5.8%) 20 (11.4%) 10 (16.7%) Malignancy (all types combined) 2 7 9 Malignancy Type* Skin 18 6 0 Lymphoma 4 5 2 Other 2 2 0 Type Not Reported * Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy. ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  35. Freedom from Malignancy For Adult Heart-Lung Recipients (Follow-ups: April 1994 June 2011) 100 % Free from Malignancy 90 80 70 All malignancy Lymphoma Skin Other 60 50 0 1 2 3 4 5 6 7 8 9 10 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  36. ADULT HEART-LUNG TRANSPLANT RECIPIENTS Cause of Death (Deaths: January 1992 June 2011) CAUSE OF DEATH 0-30 Days (N = 385) 31 Days - 1 Year (N = 311) >1 Year - 3 Years (N = 250) >3 Years - 5 Years (N = 160) >5 Years (N = 393) BRONCHIOLITIS 0 11 (3.5%) 62 (24.8%) 36 (22.5%) 80 (20.4%) ACUTE REJECTION 7 (1.8%) 9 (2.9%) 5 (2.0%) 2 (1.3%) 3 (0.8%) LYMPHOMA 0 11 (3.5%) 15 (6.0%) 8 (5.0%) 11 (2.8%) MALIGNANCY, OTHER 1 (0.3%) 4 (1.3%) 10 (4.0%) 5 (3.1%) 23 (5.9%) CMV 0 2 (0.6%) 0 1 (0.6%) 1 (0.3%) INFECTION, NON-CMV 68 (17.7%) 109 (35.0%) 74 (29.6%) 44 (27.5%) 97 (24.7%) GRAFT FAILURE 109 (28.3%) 67 (21.5%) 34 (13.6%) 26 (16.3%) 54 (13.7%) CARDIOVASCULAR 28 (7.3%) 12 (3.9%) 19 (7.6%) 14 (8.8%) 34 (8.7%) TECHNICAL 86 (22.3%) 10 (3.2%) 3 (1.2%) 3 (1.9%) 3 (0.8%) OTHER 86 (22.3%) 76 (24.4%) 28 (11.2%) 21 (13.1%) 87 (22.1%) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  37. ADULT HEART-LUNG TRANSPLANT RECIPIENTS Relative Incidence of Leading Causes of Death (Deaths: January 1992 June 2011) Bronchiolitis Infection (non-CMV) Graft Failure 50 Cardiovascular Technical 40 % of Deaths 30 20 10 0 0-30 Days (N = 385) >5 Years (N = 393) 31 Days 1 Year (N = 311) >1 Year 3 Years (N = 250) >3 Years 5 Years (N = 160) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  38. HEART-LUNG TRANSPLANTATION Pediatric Recipients ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  39. AGE DISTRIBUTION OF PEDIATRIC HEART-LUNG RECIPIENTS (Transplants: January 1982 - June 2011) 400 381 350 Number of Transplants 300 250 200 165 150 105 100 50 21 0 <1 1-5 Recipient Age (Years) 6-11 12-17 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  40. AGE DISTRIBUTION FOR DONORS OF PEDIATRIC HEART-LUNG RECIPIENTS Transplants: January 1982 - June 2011 400 376 350 Number of Transplants 300 250 200 150 109 100 56 39 50 6 0 0-11 12-17 18-34 35-49 50-59 Donor Age (Years) ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  41. AGE DISTRIBUTION OF PEDIATRIC HEART-LUNG RECIPIENTS BY YEAR 65 60 12-17 Years 1-11 Years <1 Year 55 Number of Transplants 50 45 40 35 30 25 20 15 10 5 0 NOTE: This figure includes only the heart-lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as evidence that the number of pediatric heart-lung transplants worldwide has declined in recent years. ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  42. AGE DISTRIBUTION OF PEDIATRIC HEART-LUNG RECIPIENTS BY ERA OF TRANSPLANT 100% 12-17 Years 90% 80% 1-11 Years % of Transplants 70% <1 Year 60% 50% 40% 30% 20% 10% 0% 1997-6/2011 1982-1996 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  43. NUMBER OF CENTERS REPORTING PEDIATRIC HEART-LUNG TRANSPLANTS 30 N of Pediatric Transplant Centers 25 20 15 10 5 0 Transplant Year ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  44. NUMBER OF CENTERS REPORTING PEDIATRIC HEART-LUNG TRANSPLANTS Stratified by center volume 30 N of Pediatric Transplant Centers 1-4/yr 5-9/yr 25 10-19/yr 20-29/yr 20 15 10 5 0 Transplant Year ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  45. DIAGNOSIS IN PEDIATRIC HEART-LUNG TRANSPLANT RECIPIENTS (Transplants: 1986-2010) 24% Acquired Heart Disease CF Congenital (other) Eisenmenger's Syndrome IPF IPAH Retx: Non-OB Retx: OB Other 2% 2% Other includes Bronchiectasis, Alpha-1, and OB (non-ReTX) 2% 4% 12% 4% 22% 28% 100 Cystic Fibrosis Congenital IPAH % of Cases 75 50 25 0 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 NOTE: Unknown diagnoses were excluded from this tabulation. 2012

  46. PEDIATRIC HEART-LUNG TRANSPLANTS Age Distribution By Location (Transplants: January 2000 June 2011) 0-5 years 6-11 years 12-17 years 100% 80% % of Transplants 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  47. PEDIATRIC HEART-LUNG TRANSPLANTS Diagnosis Distribution By Location (Transplants: January 2000 June 2011) Congenital heart disease Cystic Fibrosis IPAH Other 100% 80% % of Transplants 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  48. PEDIATRIC HEART-LUNG TRANSPLANTS Donor Age Distribution By Location (Transplants: January 2000 June 2011) 0-5 6-11 12-17 18-34 35-49 100% 80% % of Donors 60% 40% 20% 0% Europe North America Other ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  49. PEDIATRIC HEART-LUNG TRANSPLANTS Kaplan-Meier Survival By Diagnosis (Transplants: January 1990 - June 2010) 100 Congenital (N = 97) Eisenmenger's Syndrome (N = 51) IPAH (N = 107) 75 HALF-LIFE Congenital: 1.9 Years; Eisenmenger's: 2.6 Years; IPAH: 4.7 Years Survival (%) 50 25 Congenital vs. Eisenmenger's: p = 0.2274 Congenital vs. IPAH: p = 0.0220 Eisenmenger's vs. IPAH: p = 0.4776 0 0 1 2 3 4 5 6 7 8 Years ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

  50. PEDIATRIC HEART-LUNG TRANSPLANTS Kaplan-Meier Survival (Transplants: January 1982 - June 2010) 100 < 1 (N = 21) 1-11 (N = 264) 12-17 (N = 375) Overall (N = 660) 75 Survival (%) Half-life <1: 0.2 Years; 1-11: 3.0 Years; 12-17: 3.5 Years 50 25 0-<1 vs. 1-11: p = 0.0004 0-<1 vs. 12-17: p = 0.0001 1-11 vs. 12-17: p = 0.1218 0 0 1 2 3 4 5 6 7 8 Years 9 10 11 12 13 14 15 16 17 ISHLT J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095 2012

Related


Overview of JPAC: United Kingdom Blood Transfusion and Tissue Transplantation Services

Overview of JPAC: United Kingdom Blood Transfusion and Tissue Transplantation Services

aliana
Planifiez votre transplantation hépatique en Inde | Services de transplantation

Planifiez votre transplantation hépatique en Inde | Services de transplantation

India1
Latest Research and Studies on Lung Cancer - Update May 2024

Latest Research and Studies on Lung Cancer - Update May 2024

jade
Southampton Lung Health Check Programme Overview

Southampton Lung Health Check Programme Overview

houston
Transforming Lung Cancer Care in South West: Cancer Alliance Priorities

Transforming Lung Cancer Care in South West: Cancer Alliance Priorities

joss
Radiology-Pathology Correlation Case Presentation: Ms. DR - Lung Mass Evaluation

Radiology-Pathology Correlation Case Presentation: Ms. DR - Lung Mass Evaluation

ottoline
Donor-Specific Antibodies in Kidney Transplantation

Donor-Specific Antibodies in Kidney Transplantation

antony
Pioneering Pediatric Transplantation Initiatives

Pioneering Pediatric Transplantation Initiatives

mkry
Enhancing Heart-Lung Allocation Policy for Organ Transplantation

Enhancing Heart-Lung Allocation Policy for Organ Transplantation

mcall
Community Programs for Outcome Data Analysis in Stem Cell Transplantation

Community Programs for Outcome Data Analysis in Stem Cell Transplantation

yuj_gil
Lung Cancer Questions and Answers

Lung Cancer Questions and Answers

jaz_m
Comprehensive IGRT Lung Module for Radiation Therapy Education

Comprehensive IGRT Lung Module for Radiation Therapy Education

pre_rid
Organ Donation and Transplantation Myths True or False

Organ Donation and Transplantation Myths True or False

cseve
Overview of Respiratory System Components and Functions

Overview of Respiratory System Components and Functions

amberly
Optimization of Heart-Lung Allocation Policy for Organ Procurement Organizations (OPOs)

Optimization of Heart-Lung Allocation Policy for Organ Procurement Organizations (OPOs)

dkis
Comprehensive Update on Lung Cancer Diagnosis and Management According to 2019 NICE Guidelines

Comprehensive Update on Lung Cancer Diagnosis and Management According to 2019 NICE Guidelines

vanorman_s
Targeted Treatment Options for Lung Cancer Patients

Targeted Treatment Options for Lung Cancer Patients

hey_st
Liver and Intestinal Organ Transplantation Committee Update Report

Liver and Intestinal Organ Transplantation Committee Update Report

srust
mTOR Inhibitors in Liver Transplantation for HCC: Recent Updates and Clinical Trials

mTOR Inhibitors in Liver Transplantation for HCC: Recent Updates and Clinical Trials

hott_e
Iron Overload and Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Overview

Iron Overload and Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Overview

dresha
Allogeneic Hematopoietic Stem Cell Transplantation Overview

Allogeneic Hematopoietic Stem Cell Transplantation Overview

tpetw
Inhibition of TNKS for Lung Cancer Growth Reduction

Inhibition of TNKS for Lung Cancer Growth Reduction

torrence_c

More Related Content